Update: On November 20, 2024, the Competition Tribunal dismissed JAMP’s application for leave.
JAMP filed an application with the Competition Tribunal on July 26, 2024, seeking leave to bring an abuse of dominance case against Janssen relating to ustekinumab (Janssen’s STELARA).
JAMP proposes to allege that its ustekinumab biosimilar (JAMTEKI) business, or alternatively its biosimilars business, has been significantly harmed by Janssen’s “gaming of the regulatory system and sham litigation” and other past or ongoing anti-competitive acts.
The pending decision as to whether JAMP can commence the case would be the Tribunal’s first decision under recent Competition Act provisions permitting private parties to apply to bring an abuse of dominance application. Case details are available to view online.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
2024 highlights in Canadian life sciences IP and regulatory law
In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
Competition Tribunal refuses JAMP leave to commence ustekinumab abuse of dominance application
JAMP launched JAMTEKI, its ustekinumab biosimilar of STELARA, on March 1, 2024. Janssen launched its second branded ustekinumab product, FINLIUS, on July 2, 2024. JAMP commenced its application for ...Read More -
Federal Court rules on patent listing again, confirms generic not required to address patent submitted before ANDS filing but listed after
On January 20, 2025, Justice O’Reilly of the Federal Court dismissed Bayer’s judicial review of the Minister of Health’s decision to list Canadian Patent No. 2,970,315 (315 Patent) on the Patent Regis...Read More